#1 Clinical Trials Search in Europe

Pritelivir

Pritelivir is an innovative antiviral medication currently undergoing clinical trials for the treatment of herpes simplex virus (HSV) infections. This article explores the latest research on pritelivir’s efficacy, safety, and potential applications in managing both acyclovir-resistant and acyclovir-susceptible HSV infections, particularly in immunocompromised patients.

Table of Contents

What is Pritelivir?

Pritelivir is a new antiviral drug being developed to treat infections caused by the herpes simplex virus (HSV). It is also known by the name AIC316[1]. Pritelivir is still in the research and development phase, which means it is not yet widely available for general use. Scientists are conducting various studies to determine its effectiveness and safety in treating herpes infections[2].

How Does Pritelivir Work?

Pritelivir works differently from other antiviral drugs used to treat herpes. It targets a specific protein in the virus called the helicase-primase enzyme complex. By blocking this protein, pritelivir prevents the virus from replicating (making copies of itself) in the body. This unique mechanism of action makes pritelivir potentially effective against herpes viruses that have become resistant to other treatments[3].

What Conditions Does Pritelivir Treat?

Pritelivir is being studied for the treatment of several conditions caused by herpes simplex viruses:

  • Genital Herpes (HSV-2): This is a sexually transmitted infection that causes painful blisters or sores in the genital area[1].
  • Herpes Labialis (Cold Sores): These are painful blisters that appear on or around the lips, caused by HSV-1[4].
  • Acyclovir-Resistant HSV Infections: These are herpes infections that don’t respond to standard treatments like acyclovir, particularly in people with weakened immune systems[3].

How is Pritelivir Administered?

Pritelivir is being tested in different forms:

  • Oral tablets: Taken by mouth, usually once daily. In some studies, patients take a higher “loading dose” on the first day to quickly reach an effective level of the drug in the body[2].
  • Topical ointment: Applied directly to the skin for conditions like cold sores. In one study, it was applied 5 times daily for 4 days[4].

Clinical Trials and Research

Several clinical trials are being conducted to evaluate pritelivir’s effectiveness and safety:

  • Genital Herpes Studies: Researchers are comparing pritelivir to existing treatments like valacyclovir to see if it’s better at reducing viral shedding (when the virus is active and potentially contagious) and preventing outbreaks[5].
  • Acyclovir-Resistant HSV Studies: These trials are testing pritelivir in people with herpes infections that don’t respond to standard treatments, especially in those with weakened immune systems[3].
  • Cold Sore Studies: Researchers are evaluating a pritelivir ointment for treating cold sores, comparing it to placebo and existing treatments like Zovirax cream[4].

Safety and Side Effects

As pritelivir is still in the research phase, its full safety profile is not yet known. Researchers are carefully monitoring for potential side effects during clinical trials. Some areas of focus include:

  • Kidney function: Researchers are checking if pritelivir affects the kidneys[3].
  • Heart effects: Studies are being done to see if pritelivir affects heart rhythm[6].
  • Blood tests: Researchers are monitoring for any changes in blood cell counts or other laboratory values[3].

It’s important to note that all medications can have side effects, and the benefits and risks must be carefully weighed by healthcare providers.

Comparison to Other Treatments

Researchers are comparing pritelivir to existing herpes treatments like valacyclovir and foscarnet. Some potential advantages of pritelivir include:

  • Different mechanism of action: This means it might work when other drugs fail[3].
  • Potentially longer-lasting effect: Some studies suggest pritelivir might control the virus for a longer time between doses[5].
  • Possible effectiveness against resistant viruses: Pritelivir might work against herpes viruses that have become resistant to other drugs[3].

However, more research is needed to fully understand how pritelivir compares to existing treatments in terms of effectiveness and safety.

Aspect Details
Drug Name Pritelivir (also known as AIC316)
Primary Use Treatment of herpes simplex virus (HSV) infections
Target Population Patients with HSV-1 or HSV-2 infections, including immunocompromised individuals and those with acyclovir-resistant infections
Administration Oral tablets, typically 100 mg daily with a 400 mg loading dose
Key Clinical Trials Studies on efficacy against genital herpes, acyclovir-resistant infections, and comparisons with existing treatments like valacyclovir
Safety Monitoring Ongoing evaluations for effects on kidney function, blood cells, heart rhythm, and other potential side effects
Current Status In various phases of clinical trials, including expanded access programs for certain patient groups

FAQ

  • What is pritelivir? Pritelivir is a new antiviral drug being developed to treat herpes simplex virus (HSV) infections. It works differently from existing treatments and shows promise in managing both regular and drug-resistant HSV infections.
  • How is pritelivir taken? Pritelivir is typically taken as an oral tablet. In clinical trials, it is often administered as a 100 mg daily dose, with an initial loading dose of 400 mg on the first day to quickly reach effective levels in the body.
  • What types of HSV infections can pritelivir potentially treat? Pritelivir is being studied for various HSV infections, including genital herpes caused by HSV-2 and acyclovir-resistant mucocutaneous HSV infections in people with weakened immune systems.
  • How does pritelivir compare to existing treatments? Studies are comparing pritelivir to current treatments like valacyclovir and foscarnet. Early results suggest pritelivir may be effective against HSV strains that are resistant to commonly used drugs like acyclovir.
  • What are the potential side effects of pritelivir? While full safety data is still being collected, clinical trials are monitoring for various side effects, including impacts on kidney function, blood cell counts, and heart rhythm. As with any new medication, thorough safety evaluations are ongoing.

Ongoing Clinical Trials on Pritelivir

  • Study on Pritelivir for Treating Acyclovir-Resistant Herpes Simplex Virus in Immunocompromised Patients

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France Germany Greece Italy

Glossary

  • Acyclovir-resistant: A condition where the herpes simplex virus does not respond to treatment with acyclovir, a common antiviral medication.
  • Immunocompromised: Having a weakened immune system, which can be due to certain diseases or medical treatments, making a person more susceptible to infections.
  • Mucocutaneous: Referring to the areas where mucous membranes and skin meet, such as the lips, genitals, or anus, which are common sites for herpes infections.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Shedding rate: The rate at which a virus is released from infected cells, potentially leading to transmission of the infection.
  • QT interval: A measurement on an electrocardiogram (ECG) that represents the time it takes for the heart's electrical system to fire and then recharge. It's important in assessing the safety of new drugs.
  • Expanded access program: A program that allows patients with serious or life-threatening conditions to access experimental treatments that have not yet been approved by regulatory agencies.

References

  1. https://clinicaltrials.gov/study/NCT01047540
  2. https://clinicaltrials.gov/study/NCT05513625
  3. https://clinicaltrials.eu/trial/study-on-pritelivir-for-treating-acyclovir-resistant-herpes-simplex-virus-in-immunocompromised-patients/
  4. https://clinicaltrials.gov/study/NCT02871492
  5. https://clinicaltrials.gov/study/NCT01658826
  6. https://clinicaltrials.gov/study/NCT05671029